American Diabetes Association
Supplemental_Table_1.pdf (114.85 kB)

Plasma ApoM levels and Progression to Kidney Dysfunction in Type 1 Diabetics

Download (114.85 kB)
posted on 2022-05-12, 22:09 authored by Nathaniel L Baker, Samar M Hammad, Kelly J Hunt, Andrea Semler, Richard L Klein, Maria F Lopes-Virella


Apolipoprotein M (apoM), primarily carried by HDL, has been associated with several conditions including cardiovascular disease and diabetic nephropathy. This study proposes to examine whether plasma apoM levels are associated with the development of diabetic kidney disease, assessed as progression to macroalbuminuira and chronic kidney disease.

Plasma apoM was measured using an enzyme immunoassay in 386 subjects from the DCCT/EDIC cohort at DCCT entry and closeout and the concentrations used to determine the association with risk of progression to kidney dysfunction from the time of measurement through 18 years of EDIC follow-up. 

ApoM levels, at DCCT baseline, were higher in patients who developed CKD than in those who retained normal renal function. At DCCT closeout, participants who progressed to MA, CKD or both MA and CKD had also significantly higher apoM levels than those who remained normal and increased levels of apoM were associated with increased risk of progression to both MA [RR=1.30 (95% CI=1.01,1.66)] and CKD [RR=1.69 (95% CI=1.18,2.44)].

Our results strongly suggest that alterations in Apo M and therefore in the composition and function of HDL in type 1 diabetes is present early in the disease process and it is associated with the development of nephropathy.


This work was supported by the grant R01 DK081352 funded by NIH/NIDDK. The work was also supported by the Research Service of the Ralph H. Johnson Department of the Veterans Affairs Medical Center. The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government. The DCCT/EDIC was sponsored through research contracts from the Division of Diabetes, Endocrinology and Metabolic Diseases (NIDDK) of the NIH. Additional support was provided by the National Center for Research Resources through the GCRC program and by Genentech Inc through a Cooperative Research and Development Agreement with the NIDDK.


Usage metrics



    Ref. manager